Malak Alharbi, Hematology Oncology Fellow at Roswell Park Comprehensive Cancer Center, shared a post on LinkedIn:
“I am thrilled to share our recent collaboration with our breast pathology colleagues, exploring breast biomarkers evolution between primary and distant metastasis.
Biomarker evolution rates were 22.4% when tumors were classified into three clinical profiles, increasing to 36.6% with five profiles. Classifying tumors into five clinical profiles correlated with OS, unlike the three-profile approach.
With hormone receptor (HR) discordance were associated with worse OS.”
Breast biomarkers evolution between primary and distant metastasis: incidence and significance
Authors: Maha Khedr, Shipra Gandhi, Arya Mariam Roy, Malak Alharbi, Anthony George, Kristopher Attwood, Thaer Khoury
